The EMSY Gene Collaborates with CCND1 in Non-Small Cell Lung Carcinogenesis

Overview

Journal Int J Med Sci

Specialty General Medicine

Date 2017 Aug 22

PMID 28824300

Citations 8

Authors

Onur Baykara

Nejat Dalay

Burak Bakir

Pelin Bulut

Kamil Kaynak

Nur Buyru

Affiliations

Soon will be listed here.

Abstract

Lung cancer is the leading cause of cancer deaths. The main risk factor is smoking but the risk is also associated with various genetic and epigenetic components in addition to environmental factors. Increases in the gene copy numbers due to chromosomal amplifications constitute a common mechanism for oncogene activation. A gene-dense region on chromosome 11q13 which harbors four core regions that are frequently amplified, has been associated with various types of cancer. The important cell cycle regulatory protein cyclin D1 (CCND1) is an essential driver of the first core region of the Chr11q13 amplicon. Deregulation of CCND1 has been associated with different kinds of human malignancies including lung cancer. The EMSY (c11orf30) gene has been proposed as the possible driver of the fourth core of the 11q13 amplicon and its amplification has been associated with breast and ovarian cancers. There is no report in the literature investigating the EMSY gene in lung cancer. In this study, expression levels of the EMSY and CCND1 genes were investigated in 85 patients with non small cell lung cancer by Real Time PCR. Expression of the EMSY and CCND1 genes were increased in 56 (65.8%) and 50 (58.8%) of the patients, respectively. Both genes showed a higher expression in the tumors when compared to normal tissues. A strong correlation was present between the expression rates of both genes (p<0.001). Patients with adenocarcinoma had higher expression levels of both genes (p=0.02). We conclude that EMSY and CCND1 work in collaboration and contribute to the pathogenesis of lung cancer.

Citing Articles

Construction of a miRNA Panel for Differentiating Lung Adenocarcinoma Brain Metastases and Glioblastoma.

Torner B, Geczi D, Klekner A, Balogh I, Penyige A, Birko Z Cancers (Basel). 2025; 17(4).

PMID: 40002176 PMC: 11853152. DOI: 10.3390/cancers17040581.

Targeting EMSY-mediated methionine metabolism is a potential therapeutic strategy for triple-negative breast cancer.

Liu C, Chen L, Cai Y, Chen Y, Liu Y, Zhou Y Cell Rep Med. 2024; 5(2):101396.

PMID: 38290515 PMC: 10897545. DOI: 10.1016/j.xcrm.2024.101396.

Single-cell RNA-seq reveals the immune escape and drug resistance mechanisms of mantle cell lymphoma.

Wang L, Mo S, Li X, He Y, Yang J Cancer Biol Med. 2020; 17(3):726-739.

PMID: 32944402 PMC: 7476085. DOI: 10.20892/j.issn.2095-3941.2020.0073.

Network Pharmacology Study on the Pharmacological Mechanism of Cinobufotalin Injection against Lung Cancer.

Mao Y, Peng X, Xue P, Lu D, Li L, Zhu S Evid Based Complement Alternat Med. 2020; 2020:1246742.

PMID: 32148531 PMC: 7048923. DOI: 10.1155/2020/1246742.

Downregulation of TCEAL7 expression induces CCND1 expression in non-small cell lung cancer.

Orhan C, Bulut P, Dalay N, Ersen E, Buyru N Mol Biol Rep. 2019; 46(5):5251-5256.

PMID: 31321645 DOI: 10.1007/s11033-019-04982-6.

References

Elsheikh S, Green A, Aleskandarany M, Grainge M, Paish C, Lambros M . CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome. Breast Cancer Res Treat. 2007; 109(2):325-35. DOI: 10.1007/s10549-007-9659-8. View

van Hattem W, Carvalho R, Li A, Offerhaus G, Goggins M . Amplification of EMSY gene in a subset of sporadic pancreatic adenocarcinomas. Int J Clin Exp Pathol. 2008; 1(4):343-51. PMC: 2480540. View

Xu J, Tyan T, Cedrone E, Savaraj N, Wang N . Detection of 11q13 amplification as the origin of a homogeneously staining region in small cell lung cancer by chromosome microdissection. Genes Chromosomes Cancer. 1996; 17(3):172-8. DOI: 10.1002/(SICI)1098-2264(199611)17:3<172::AID-GCC5>3.0.CO;2-1. View

Bocanegra M, Bergamaschi A, Kim Y, Miller M, Rajput A, Kao J . Focal amplification and oncogene dependency of GAB2 in breast cancer. Oncogene. 2009; 29(5):774-9. DOI: 10.1038/onc.2009.364. View

Brown L, Irving J, Parker R, Kim H, Press J, Longacre T . Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecol Oncol. 2005; 100(2):264-70. DOI: 10.1016/j.ygyno.2005.08.026. View

Schwab M . Amplification of oncogenes in human cancer cells. Bioessays. 1998; 20(6):473-9. DOI: 10.1002/(SICI)1521-1878(199806)20:6<473::AID-BIES5>3.0.CO;2-N. View

Garapaty S, Xu C, Trojer P, Mahajan M, Neubert T, Samuels H . Identification and characterization of a novel nuclear protein complex involved in nuclear hormone receptor-mediated gene regulation. J Biol Chem. 2009; 284(12):7542-52. PMC: 2658049. DOI: 10.1074/jbc.M805872200. View

Luk C, Tsao M, Bayani J, Shepherd F, Squire J . Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization. Cancer Genet Cytogenet. 2001; 125(2):87-99. DOI: 10.1016/s0165-4608(00)00363-0. View

Berrieman H, Ashman J, Cowen M, Greenman J, Lind M, Cawkwell L . Chromosomal analysis of non-small-cell lung cancer by multicolour fluorescent in situ hybridisation. Br J Cancer. 2004; 90(4):900-5. PMC: 2410166. DOI: 10.1038/sj.bjc.6601569. View

10.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

11.

Musgrove E, Caldon C, Barraclough J, Stone A, Sutherland R . Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 2011; 11(8):558-72. DOI: 10.1038/nrc3090. View

12.

Sellers T, Bailey-Wilson J, Elston R, Wilson A, Elston G, Ooi W . Evidence for mendelian inheritance in the pathogenesis of lung cancer. J Natl Cancer Inst. 1990; 82(15):1272-9. DOI: 10.1093/jnci/82.15.1272. View

13.

Brennan P, Hainaut P, Boffetta P . Genetics of lung-cancer susceptibility. Lancet Oncol. 2010; 12(4):399-408. DOI: 10.1016/S1470-2045(10)70126-1. View

14.

Couraud S, Zalcman G, Milleron B, Morin F, Souquet P . Lung cancer in never smokers--a review. Eur J Cancer. 2012; 48(9):1299-311. DOI: 10.1016/j.ejca.2012.03.007. View

15.

Vaziri S, Tubbs R, Darlington G, Casey G . Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers. Mol Pathol. 2001; 54(4):259-63. PMC: 1187078. DOI: 10.1136/mp.54.4.259. View

16.

Gibcus J, Kok K, Menkema L, Hermsen M, Mastik M, Kluin P . High-resolution mapping identifies a commonly amplified 11q13.3 region containing multiple genes flanked by segmental duplications. Hum Genet. 2006; 121(2):187-201. DOI: 10.1007/s00439-006-0299-6. View

17.

Rodriguez C, Hughes-Davies L, Valles H, Orsetti B, Cuny M, Ursule L . Amplification of the BRCA2 pathway gene EMSY in sporadic breast cancer is related to negative outcome. Clin Cancer Res. 2004; 10(17):5785-91. DOI: 10.1158/1078-0432.CCR-03-0410. View

18.

Ramalingam S, Owonikoko T, Khuri F . Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin. 2011; 61(2):91-112. DOI: 10.3322/caac.20102. View

19.

Altinisik J, Karateke A, Coksuer H, Ulutin T, Buyru N . Expression of EMSY gene in sporadic ovarian cancer. Mol Biol Rep. 2010; 38(1):359-63. DOI: 10.1007/s11033-010-0116-0. View

20.

Hung R, McKay J, Gaborieau V, Boffetta P, Hashibe M, Zaridze D . A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 2008; 452(7187):633-7. DOI: 10.1038/nature06885. View